Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - Sanara MedTech Inc. | smti_ex991.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): April 17,
2020
SANARA MEDTECH INC.
(Exact name of registrant as specified in its
charter)
|
Texas
|
000-11808
|
59-2219994
|
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(I.R.S.
Employer Identification No.)
|
1200
Summit Avenue, Suite 414
|
Fort
Worth, Texas
|
76102
|
|
(Address
of principal executive offices)
|
(zip
code)
|
Registrant’s telephone number, including area code:
(817)-529-2300
Securities
registered pursuant to Section 12(b) of the Act: None
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company
as defined in in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this
chapter).
Emerging growth company ☐
If an emerging growth company, indicate by
checkmark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the
Exchange Act. ☐
Item
2.02 Results of Operations and Financial Condition
On
April 17, 2020, Sanara MedTech Inc. (the “Company”)
issued a press release announcing first quarter 2020 revenues and
the impact of COVID-19 on the Company’s operations. A copy of
the Company’s press release is attached as
Exhibit 99.1 to this Current Report on Form 8-K.
Item
9.01 Financial Statements and Exhibits
(d)
Exhibits:
|
Exhibit No.
|
Description
|
|
Press Release
issued April 17, 2020, filed herewith.
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Company has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
Sanara
MedTech Inc.
|
|
|
|
|
|
|
|
|
Date: April
17, 2020
|
By:
|
/s/ Michael
D. McNeil
|
|
|
|
|
Name: Michael
D. McNeil
|
|
|
|
|
Title: Chief
Financial Officer
|
|